
ANRO Stock Forecast & Price Target
ANRO Analyst Ratings
Bulls say
Alto Neuroscience is positioned to succeed with a strong pipeline of clinical-stage assets targeting depressive and schizophrenia disorders using individual neurobiology to develop personalized and effective treatments. The company has a solid cash runway through 2029, and the Phase 2b study for ALTO-207 is now recruiting with data expected in 2H27. Additionally, the company has implemented trial-quality safeguards to improve the interpretability of upcoming data and is advanced under the 505(b)(2) pathway, further minimizing regulatory risk.
Bears say
Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. Despite the company's promising pipeline and unique approach, there are several fundamental reasons for a negative outlook. These reasons include delays in the timing of top-line results for key clinical trials, high failure rates in depression research, unproven biomarker approach, reliance on third parties for supply and manufacturing, and the need for additional capital before profitability is achieved. These factors contribute to the company's high clinical and financial risks, making it difficult to accurately evaluate and assign a target price.
This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.
ANRO Analyst Forecast & Price Prediction
Start investing in ANRO
Order type
Buy in
Order amount
Est. shares
0 shares